Uveitis Clinical Trial - Optical Coherence Tomography (OCT) in Uveitis

Status Recruiting

Clinical Trial Summary

Optical Coherence Tomography (OCT) machines are non-contact instruments that can provide micrometer (one one-thousandths) scale imaging of biological tissue. This allows excellent assessment of the white blood and inflammatory cells seen in uveitis, an inflammation of any or all parts of the uvea (iris, ciliary body, choroid).

Clinical Trial Description

In uveitis, white blood and inflammatory cells can enter the anterior chamber of the eye and adhere to the back surface of the cornea or enter the space between the lens and the retina in various types of uveitis. Transparency of the clear fluid that fills the space between the cornea and the lens (or between the lens and the retina) can be reduced due to the inflammation reaction of the eye. The amounts of these cells and reduced transparency that are present indicate the level of severity of inflammation. The primary goal of this study is to use OCT to standardize anterior chamber (AC) cell grading. Another goal is to discover whether the size of cells and particles in the AC measured by OCT differs between uveitis diagnostic categories. OCT will also be used to detect protein concentration increases within the clear fluid inside the eye and determine if the concentration increase correlates with findings from the usual slit lamp grading method. Background data including age, sex, medical history, and eye history will be gathered prior to the study/OCT testing visit. Other standard-of-care testing, like visual acuity and slit lamp (biomicroscope) exam will be performed to see if there is evidence of uveitis that meets the inclusion criteria for this study. If so, grading of the eye inflammation will be performed as defined by the Standardization of Uveitis Nomenclature (SUN). Once enrolled in the study, subjects will then undergo OCT testing with the study device to assess AC cells, AC flare (increased protein), keratic precipitates (cells adhered to back surface of cornea), and vitreous cells & haze (increased opacities in vitreous gel). OCT Procedure: The subject will be seated and have their head positioned on a chin rest. They will be asked to look at a target (a lighted spot) while a beam of light scans the front part of the eye. The light is infrared and will not be visible or cause any sensation. A cotton tip swab may be used to help hold the eyelid open temporarily if necessary. ;

Study Design

Related Conditions & MeSH terms

Uveitis

Clinical Trial Details

NCT number	NCT02026128
Study type	Observational
Source	Oregon Health and Science University
Contact	Denny Romfh, OD
Phone	503-494-4351
Email	romfhd@ohsu.edu
Status	Recruiting
Phase
Start date	March 2012
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Active, not recruiting	`NCT04704609` - Imaging Quantification of Inflammation (IQI)
Completed	`NCT03173144` - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn	`NCT01280669` - Intravitreal Sirolimus as Therapeutic Approach to Uveitis	Phase 2
Terminated	`NCT02907814` - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography	N/A
Active, not recruiting	`NCT02252328` - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients	Phase 2/Phase 3
Completed	`NCT04183387` - Simvastatin in Uveitis	Phase 2
Completed	`NCT01983488` - Clinical Outcome in Uveitis
Withdrawn	`NCT00499551` - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis	Phase 1/Phase 2
Completed	`NCT00476593` - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications	N/A
Completed	`NCT00132691` - Multicenter Uveitis Steroid Treatment (MUST) Trial	Phase 4
Terminated	`NCT00114062` - Study to Treat Uveitis Associated Macular Edema	Phase 2
Completed	`NCT00001867` - Effect of Pregnancy on Uveitis	N/A
Completed	`NCT00379275` - Eye and Immunogenetic Features of Sarcoidosis	N/A
Active, not recruiting	`NCT03828019` - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial	Phase 3
Terminated	`NCT01939691` - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial	Phase 4
Active, not recruiting	`NCT03889860` - Objective Choroidal Thickness Measurements in Uveitis
Completed	`NCT00070759` - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis	Phase 2
Recruiting	`NCT05486468` - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment	Phase 3
Active, not recruiting	`NCT05385757` - UNICORNS: Uveitis in Childhood Prospective National Cohort Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.